Wall Street analysts expect Supernus Pharmaceuticals Inc (NASDAQ:SUPN) to announce sales of $109.26 million for the current quarter, according to Zacks. Four analysts have made estimates for Supernus Pharmaceuticals’ earnings. The highest sales estimate is $111.45 million and the lowest is $106.20 million. Supernus Pharmaceuticals reported sales of $103.00 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 6.1%. The business is expected to announce its next quarterly earnings report on Tuesday, November 5th.

On average, analysts expect that Supernus Pharmaceuticals will report full-year sales of $414.98 million for the current fiscal year, with estimates ranging from $410.90 million to $419.58 million. For the next fiscal year, analysts forecast that the company will report sales of $451.75 million, with estimates ranging from $435.77 million to $466.80 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Supernus Pharmaceuticals.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $0.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.05. Supernus Pharmaceuticals had a net margin of 25.66% and a return on equity of 22.36%. The business had revenue of $104.70 million during the quarter, compared to the consensus estimate of $109.67 million. During the same quarter last year, the firm posted $0.57 EPS. Supernus Pharmaceuticals’s revenue was up 5.2% compared to the same quarter last year.

SUPN has been the subject of several research reports. Mizuho reissued a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, August 7th. Cowen set a $50.00 price target on shares of Supernus Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 7th. Jefferies Financial Group set a $46.00 price target on shares of Supernus Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 30th. Stifel Nicolaus set a $55.00 price target on shares of Supernus Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 7th. Finally, TheStreet downgraded shares of Supernus Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Thursday, August 29th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $53.38.

NASDAQ SUPN traded down $0.69 during mid-day trading on Monday, hitting $27.89. The company’s stock had a trading volume of 565,022 shares, compared to its average volume of 544,008. The company’s 50 day simple moving average is $28.86 and its 200 day simple moving average is $33.29. Supernus Pharmaceuticals has a twelve month low of $25.32 and a twelve month high of $51.38. The company has a current ratio of 2.72, a quick ratio of 2.53 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $1.48 billion, a price-to-earnings ratio of 13.60, a PEG ratio of 0.99 and a beta of 1.62.

In other news, CEO Jack A. Khattar acquired 7,200 shares of the business’s stock in a transaction on Friday, August 23rd. The shares were purchased at an average cost of $26.39 per share, with a total value of $190,008.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 6.57% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Municipal Employees Retirement System of Michigan boosted its holdings in Supernus Pharmaceuticals by 2.2% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 15,650 shares of the specialty pharmaceutical company’s stock worth $518,000 after acquiring an additional 330 shares during the last quarter. Bridge City Capital LLC raised its stake in shares of Supernus Pharmaceuticals by 0.5% during the 2nd quarter. Bridge City Capital LLC now owns 69,000 shares of the specialty pharmaceutical company’s stock worth $2,283,000 after purchasing an additional 338 shares during the period. Oregon Public Employees Retirement Fund raised its stake in shares of Supernus Pharmaceuticals by 1.8% during the 1st quarter. Oregon Public Employees Retirement Fund now owns 20,239 shares of the specialty pharmaceutical company’s stock worth $709,000 after purchasing an additional 366 shares during the period. Baltimore Washington Financial Advisors Inc. raised its stake in shares of Supernus Pharmaceuticals by 0.9% during the 2nd quarter. Baltimore Washington Financial Advisors Inc. now owns 45,033 shares of the specialty pharmaceutical company’s stock worth $1,490,000 after purchasing an additional 420 shares during the period. Finally, Diversified Trust Co raised its stake in shares of Supernus Pharmaceuticals by 8.4% during the 2nd quarter. Diversified Trust Co now owns 6,450 shares of the specialty pharmaceutical company’s stock worth $213,000 after purchasing an additional 500 shares during the period. 99.35% of the stock is currently owned by hedge funds and other institutional investors.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

Featured Article: What is Green Investing?

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.